Program Subsidiary News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Program Subsidiary. Real-time updates on events, politics, business and more.

Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary

February 9, 2023

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus La

United States Ramona Sequeira Megan Ostrower Christopher Oreilly Nimbus Lakshmi Inc Exchange Commission

Source: caribbeannewsglobal.com

Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

December 13, 2022

13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases ...

United States United Kingdom Catherine Wilson Nimbus Therapeutics Takeda Yakuhin Kogyo Jeb Keiper

Source: wallstreet-online.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Program Subsidiary News Today

Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary

Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

Explore More Categories